Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence.
about
Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtypeA phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursPreventability of cancer: the relative contributions of biologic and social and physical environmental determinants of cancer mortalityBody mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor statusMenopausal hormone therapy and breast cancer mortality: clinical implicationsThe National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trialGenerational risks for cancers not related to tobacco, screening, or treatment in the United StatesIMS reaction to recent breast cancer data.Recent trends in breast cancer incidence in US white women by county-level urban/rural and poverty status.Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California.Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004.Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish womenRecent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohortEffect of changing breast cancer incidence rates on the calibration of the Gail model.Progesterone receptor action: defining a role in breast cancerOral bisphosphonate use and breast cancer incidence in postmenopausal women.Rates of atypical ductal hyperplasia have declined with less use of postmenopausal hormone treatment: findings from the Breast Cancer Surveillance Consortium.Recent Trends in Breast Cancer Incidence and Mortality in Germany.Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010.Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer.Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.Risk factors for ductal and lobular breast cancer: results from the nurses' health study.Breast cancer after use of estrogen plus progestin in postmenopausal women.Hormone therapy and fatal breast cancer.Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009Invasive breast cancer incidence trends by detailed race/ethnicity and age.From the ranks of mammary progesterone mediators, RANKL takes the spotlightFrom cancer screening to treatment: service delivery and referral in the National Breast and Cervical Cancer Early Detection ProgramChanging concepts: Menopausal hormone therapy and breast cancer.The biology of progesterone receptor in the normal mammary gland and in breast cancerElevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrenceA sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010.Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women.Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis.Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections.Screening mammography intervals among postmenopausal hormone therapy users and nonusers.Decline in hormone replacement prescription and fall in breast cancer incidence: an epidemiological discourse.Finally! A model for progesterone receptor action in normal human breastProportion of invasive breast cancer attributable to risk factors modifiable after menopause.
P2860
Q21195226-CB88F0CD-C567-493E-94EF-1655A753BEB7Q24653999-235500B2-829F-4867-B404-DEB42A079DCCQ26849459-3683A31B-371D-44BC-80CD-5FC80EE2B3E3Q27012792-CD2705C9-7D33-423C-9555-C185A064F914Q27022201-096A23FC-6D8D-4CB8-9CE9-DEB1B4F86C54Q28217652-819A37E3-B976-4AB3-8CEA-5ED27463DFCBQ28396486-A6033765-8710-485E-98B6-C0D5D7776EBFQ31105720-1652F37D-8775-4CEB-9852-1BE3FAACE222Q33475114-00A28B2A-0F41-488E-ACE5-07F355A089DDQ33569338-F5FA96DF-F22B-413E-8FB4-E5BCFE96F94CQ33693138-D5E0C3E2-CA41-4ED4-AC5A-A0CF5BA6A618Q33710365-52B823BE-54C4-4D7C-8250-08B17E378A45Q33892873-14E3DCE7-F361-44C4-865C-55B40AC8BCB4Q33897605-2611F550-FFC6-4682-A47C-DE4F5E40584FQ33998721-F3F63227-040B-4AFF-8DB0-6E3A8C78FE6DQ34049239-50B6843B-9F6B-427B-AF20-605E27293E7FQ34062503-FD58E78C-6C47-49D9-9368-6B1ADF9FB3D1Q34096113-A44C8819-AF33-4370-97AA-092FE5473A03Q34232032-E869B40C-780F-4A5E-A778-5578B77A42D4Q34315478-B666AAFB-062A-4F34-983C-C44098800A0CQ34555256-0D7B5284-7120-4CA0-90E0-DBE9A7EE1092Q34581334-5B1C80E4-947E-4021-ABE7-A878D81F489BQ34613642-E95373E9-03B0-4FCF-ACF6-AD782AD4EFA0Q34938322-D1BC5F1E-1ACC-4D66-B76F-BD9E00494A5FQ34994476-69F2182E-5F63-4818-A2BD-661164FE4735Q35068765-B8AE20E4-993E-4FFF-9DE5-08C2B8206E06Q35388306-E67C839F-BAD3-48BF-A8BB-3CE1FDCFFEACQ35659426-62CF48CD-490E-42C4-88D7-0DC9D77BE26FQ35694177-02F86362-CA59-4272-8840-A5F7C73E790DQ35866374-74856E08-B100-4609-830E-9338DC125B9BQ35868802-451ECE25-A934-4519-8DB5-114BB5B278BEQ36438653-2FFC374A-E98D-455E-A195-012468E4139CQ36713568-27AE4EAE-6222-4DB2-8097-9EC9D5049090Q36871025-CC33F62A-5D67-4900-9E43-50667DAF35FBQ36916147-0AABD97A-77FD-4FDF-96E7-85725ABEA144Q37122762-C4EA522E-51C0-458B-B5A3-79FB4D548F3BQ37205393-F4C8E307-977D-4FA8-B627-77CB595F18BAQ37228680-082E28F6-C20E-42BC-AD35-56D3B9D0D1EBQ37244577-1AFB469C-EFBD-441F-AA97-711C467D7A66Q37306276-1DB9DD3F-C0A4-4227-B095-AA6E15655E50
P2860
Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Recent declines in hormone the ...... and population-based evidence.
@en
Recent declines in hormone the ...... and population-based evidence.
@nl
type
label
Recent declines in hormone the ...... and population-based evidence.
@en
Recent declines in hormone the ...... and population-based evidence.
@nl
prefLabel
Recent declines in hormone the ...... and population-based evidence.
@en
Recent declines in hormone the ...... and population-based evidence.
@nl
P2093
P356
P1476
Recent declines in hormone the ...... and population-based evidence.
@en
P2093
Connie S Uratsu
Joseph V Selby
Larry H Kushi
Lisa J Herrinton
P304
P356
10.1200/JCO.2006.08.6504
P407
P577
2006-11-01T00:00:00Z